MDT-AP-2849
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- sex
- F
- new_clusters
- C4
- umap1_2d
- 4.38291735
- umap2_2d
- 3.831824355
- umap1_3d
- 1.306347696
- umap2_3d
- -0.915797527
- umap3_3d
- -1.729242676
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- KRAS_SIGNALING_UP+0.320
- TNFA_SIGNALING_VIA_NFKB+0.320
- SPERMATOGENESIS+0.280
- INFLAMMATORY_RESPONSE+0.270
- PANCREAS_BETA_CELLS+0.270
- UV_RESPONSE_DN+0.250
- COAGULATION+0.240
- MYOGENESIS+0.200
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.520
- MYC_TARGETS_V2-0.480
- MYC_TARGETS_V1-0.430
- DNA_REPAIR-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.330
- ADIPOGENESIS-0.250
- E2F_TARGETS-0.240
- G2M_CHECKPOINT-0.200
- MITOTIC_SPINDLE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-00412 | — | cohortA1 | 0.899 |
| 2 | SRR1323536 | GTEX | — | 0.886 |
| 3 | SRR821690 | GTEX | — | 0.881 |
| 4 | TCGA-93-7348-01A-21R-2039-07 | — | cohortA1 | 0.879 |
| 5 | aMVAC.P_004_TURBT_S222 | — | — | 0.879 |
| 6 | SRR1310136 | GTEX | — | 0.877 |
| 7 | 15-109pB4_FFPE | — | — | 0.875 |
| 8 | SRR1325964 | GTEX | — | 0.871 |
| 9 | BS_HHPA8NJ2 | Med | Medulloblastoma | 0.870 |
| 10 | DRR168569 | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |